Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objective: To assess the diagnostic value of the protein markers in both cirrhotic patients on top of hepatitis C virus (HCV) and in hepatocellular carcinoma (HCC) patients on top of HCV in comparison to normal controls. Methods: A total number of 100 subjects including HCC, cirrhotic patients on top of HCV and normal controls were subjected to serum protein markers analysis for alpha-fetoprotein, apolipoprotein A1, apolipoprotein A2, insulin like growth factor 1 and insulin like growth factor 1 receptor by western blotting technique. Results: It was found that alpha-fetoprotein alone could not be used as a screening test while apolipoprotein A2 as a serum marker could be used as a non invasive screening test to differentiate a case of HCC from cirrhotic HCV patient. The all four markers were able to discriminate normal persons from HCC and cirrhotic HCV patients effectively. Conclusions: We concluded that proteomics analysis being non invasive, rapid and sensitive is a novel gate that can serve in early diagnosis and screening of HCC and cirrhotic HCV patients.

Cite

CITATION STYLE

APA

Hegazy, E. A. A. A., Eissa, S. A., Abde, A. E., Sorour, H., Fouad, H. H., Abde, D., & Omran, H. (2017). Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients. Asian Pacific Journal of Tropical Disease, 7(9), 564–568. https://doi.org/10.12980/apjtd.7.2017D7-93

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free